Information  X 
Enter a valid email address

Verona Pharma plc (VRP)

  Print      Mail a friend

Friday 21 February, 2020

Verona Pharma plc

Verona Pharma plc to Announce Financial Results for Full Year Ended December 31, 2019 and Provide Corporate Update

Verona Pharma plc to Announce Financial Results for Full Year Ended December 31, 2019 and Provide Corporate Update

LONDON, Feb. 21, 2020 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM: VRP) (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases,  announces that it will report its audited financial results for the full year ended December 31, 2019 on Thursday, February 27, 2020 and host an investment community conference call at 9:00 a.m. EST / 2:00 p.m. GMT to discuss the full year financial results and provide a corporate update.

To participate, please dial one of the following numbers and reference conference ID 5394158:

  • 866-940-4574 for callers in the United States
  • 0800 028 8438 for callers in the United Kingdom
  • 0800 181 5287 for callers in Germany

A live webcast will be available on the Events and presentations link on the Investors page of the Company’s website, www.veronapharma.com, and an audio replay will be available there for 30 days.

About Verona Pharma
Verona Pharma is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for the treatment of respiratory diseases with significant unmet medical needs. If successfully developed and approved, Verona Pharma’s product candidate, ensifentrine, has the potential to be the first therapy for the treatment of respiratory diseases that combines bronchodilator and anti-inflammatory activities in one compound. Verona Pharma is currently in Phase 2 development with three formulations of ensifentrine for the treatment of COPD: nebulized, dry powder inhaler, and pressurized metered-dose inhaler. Ensifentrine also has potential applications in cystic fibrosis, asthma and other respiratory diseases. For more information, please visit www.veronapharma.com.

   
Verona Pharma plc Tel: +44 (0)20 3283 4200
David Zaccardelli, Chief Executive Officer [email protected]
David Moskowitz, VP Capital Markets Strategy & Investor Relations (Investor Enquiries)
Victoria Stewart, Director of Communications (Media Enquiries)
 
   
N+1 Singer
(Nominated Adviser and UK Broker)
Tel: +44 (0)20 3283 4200
Aubrey Powell / George Tzimas / Iqra Amin (Corporate Finance)  
Tom Salvesen (Corporate Broking)  
   
Optimum Strategic Communications
(European Media and Investor Enquiries)
Tel: +44 (0)20 950 9144
[email protected]
Mary Clark / Eva Haas / Hollie Vile  
   
Argot Partners
(US Investor Enquiries)
Tel: +1 212-600-1902
[email protected]
Stephanie Marks / Kimberly Minarovich / Michael Barron  

a d v e r t i s e m e n t